BioSpace News Archive

Headlands Research is pleased to announce that on Friday, Aug. 28, its JEM Research Institute clinical trial site in Lake Worth, Florida, successfully dosed the first North American patient in AstraZeneca’s Phase III COVID-19 vaccine trial.

TriRx Pharmaceutical Services, a global contract development and manufacturing organization (CDMO) serving the biopharmaceutical market, today announced that it has finalized an agreement with MSD Sante Animale, a division of Merck & Co., Inc., Kenilworth, N.J. , USA (NYSE:MRK), to acquire the operations and ownership of t

Joint offering pairs pharmacy supply chain management capabilities with evidence-based drug content, designed to help hospital pharmacy teams manage drug shortages

Nurx, the largest digital practice for women’s health, today introduced personalized treatment for headaches and migraines.

ResMed (NYSE: RMD, ASX: RMD) announced today the launch of its AirTouch N20 nasal mask, the company’s first CPAP nasal mask with a memory foam cushion and softest nasal mask ever.

Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today provided an update on its ongoing APVO436 Phase 1/1b clinical trial

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental New Drug Applications (sNDAs) for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor)

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, issued the following statement concerning the progress of the Company’s operations.

Kit Check, the leader in automated and intelligent medication management solutions, announced that Premier Inc. has extended its sole source partnership with the company for its Bluesight™ for Controlled Substances solution as well as its namesake kit and tray processing system.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today announced that it has submitted the first portion of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for maralixibat